SCHEMBL7735976

SCHEMBL7735976

CN(C)N1CCC(C(=O)O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
KDM4E B2RXH2 2/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TSHR P16473 2/20 0.40
CYP2C19 P33261 1/20 0.40
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRE P78334 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2692890 0.87 NOTUM (0.42) LMNAALDH1A1NOTUM
SCHEMBL8150412 0.80 SMN1; SMN2 (0.53) KDM4ETSHRGAAL3MBTL1ALDH1A1
SCHEMBL28832903 0.79 LMNA (0.47) LMNAKDM4EUSP2HPGDNPSR1
SCHEMBL1256089 0.74 MEN1 (0.61) LMNANPSR1HSD17B10GAAL3MBTL1
SCHEMBL46774 0.73 ALDH1A1 (0.55) LMNAKDM4EUSP2HPGDNPSR1
SCHEMBL3097907 0.72 LMNA (0.49) LMNANPSR1HSD17B10GAAL3MBTL1
Hydrochloric Acid SCHEMBL641317 0.71 ALDH1A1 (0.58) LMNAKDM4EUSP2HPGDNPSR1
SCHEMBL3092846 0.71 ALDH1A1 (0.53) LMNAKDM4EUSP2HPGDNPSR1
Iodide SCHEMBL30988366 0.71 ALDH1A1 (0.53) LMNAKDM4EUSP2HPGDNPSR1
Water SCHEMBL5420438 0.71 ALDH1A1 (0.53) LMNAKDM4EUSP2HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6410792-B1 OBESITY DISEASES BAYER CORPORATION 2002-06-25 US disclosed
US-6048900-A FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA BAYER CORPORATION (US) 2000-04-11 US disclosed